Burden of chemotherapy-induced neuropathy—a cross-sectional study
Open Access
- 16 November 2010
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 19 (12) , 1991-1996
Abstract
Neuropathy is a common adverse effect of chemotherapy. However, the both the prevalence and the burden of this adverse effect have been poorly documented. The aim of the study was to assess the prevalence and discomfort caused by neuropathic symptoms in relation to other adverse effects of chemotherapy. Between January 2002 and June 2004, we screened 448 patients who were treated with vinca alkaloids, taxanes or platina derivatives, using a simple questionnaire of neuropathic symptoms. The response rate was 75%. Neuropathic symptoms were reported by 258 respondents (76%), of whom 152 patients were eligible for the final analyses. The severity of neuropathy was scored using the National Cancer Institute Common Toxicity Criteria. At the screening visit, 90 patients (59%) still reported neuropathic symptoms. Tingling (71%), numbness (58%), impaired sensory function (46%) and pain in hands and feet (40%) were the most common symptoms. The median intensity of neuropathic symptoms was 28/100 on the visual analogue scale. Grade 1 sensory neuropathy was found in 19 out of 90 patients (21%), grade 2 in 38 (42%) and grade 3 in 33 (37%) patients. Grade 1 motor neuropathy was found in 28 (31%), grade 2 in 14 (16%) and grade 3 in one patient (1%). Grade 4 sensory or motor neuropathy was not seen. In the whole cohort of 152 patients, fatigue (66%), mucositis (61%) and neuropathic symptoms (59%) were the most commonly reported symptoms. Every third patient (37%) with neuropathic symptoms ranked them as the most troublesome symptom. Neuropathy is a common and troublesome adverse effect of chemotherapy, even though the intensity of the symptoms is mild. Thus, the intensity and inconvenience does not correlate to each other.Keywords
This publication has 19 references indexed in Scilit:
- Efficacy of lamotrigine in the management of chemotherapy‐induced peripheral neuropathyCancer, 2008
- Quantitative Sensory Findings in Patients With Bortezomib-Induced PainThe Journal of Pain, 2007
- Interventions for preventing neuropathy caused by cisplatin and related compounds2007
- EFNS guidelines on pharmacological treatment of neuropathic painEuropean Journal of Neurology, 2006
- Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II studyInvestigational New Drugs, 2006
- Toxic neuropathy in patients with pre-existing neuropathyNeurology, 2003
- Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathyPain, 2002
- Chemotherapy-induced peripheral neuropathyJournal of Neurology, 2002
- Grading of chemotherapy-induced peripheral neuropathyAnnals of Oncology, 2000
- Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testingJournal of Neuro-Oncology, 1997